UnknownPhase 1NCT05327426

Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT

Studying Poliomyelitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Vermont
Principal Investigator
Jessica W Crothers, MD
UVM Vaccine Testing Center
Intervention
Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT)(biological)
Enrollment
19 target
Eligibility
18-45 years · All sexes
Timeline
20222024

Study locations (1)

Collaborators

World Health Organization

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05327426 on ClinicalTrials.gov

Other trials for Poliomyelitis

Additional recruiting or active studies for the same condition.

See all trials for Poliomyelitis

← Back to all trials